Type 2 diabetes, psoriasis and thiazolidinediones

International Journal of Clinical Practice

Volumn 60, Issue 3, 2006, Pages 362-363

  Krentz, Andrew J ^a,b   Friedmann, P S ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DITHRANOL; INSULIN; INSULIN SENSITIZING AGENT; KETOCONAZOLE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BODY WEIGHT DISORDER; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; DRUG CONTRAINDICATION; FEMALE; FLUID RETENTION; HUMAN; HYPOGLYCEMIA; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RELAPSE; SIDE EFFECT; ULTRAVIOLET B RADIATION; WEIGHT GAIN;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PSORIASIS; THIAZOLIDINEDIONES;

EID: 33644753848     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00765.x     Document Type: Article

References (8)

1. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. BMJ 2000; 321: 252-3.
2. Rosen ED, Spiegelman BM. PPARγ: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
3. Ellis CN, Varani J, Fisher GJ et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000; 136: 609-16.
4. Robertshaw H, Friedmann PS. Pioglitazone: A promising new therapy for psoriasis. Br J Dermatol 2005; 152: 189-91.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
6. Nesto RW, Bell D, Bow RO et al. Thiazolidionedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and the American Diabetes Association. Circulation 2003; 108: 2941-8.
7. Yki-Järvinen H, Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.
8. Weindl G, Shäfer-Korting M, Schaller M, Korting CH. Peroxisome proliferators-activated rcceptors and their ligands. Entry into the post-glucocorticoid era of skin treatment? Drugs 2005; 65: 1919-34.